Floatz logo

Osimertinib

EGFR Mutation

Beijing Pearl Biotechnology Limited Liability CompanySmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

1 Active assets in the EGFR Mutation cohort.

Asset / SponsorPhaseRating
Panobinostat
The First Affiliated Hospital of Guangzhou Medical University
Phase 3B
Carboplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC
Metformin
Fujian Cancer Hospital
Phase 2CCC

Same molecule, other indications

Osimertinib is also rated in:

EGFR Exon 19 DeletionDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →